Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) will present at the 5th Annual Evercore ISI Virtual HealthCONx Conference on November 29, 2022, at 9:55 a.m. Central time. Key executives including Rob Michael, Jeffrey R. Stewart, Scott Reents, and Tom Hudson will participate in the session. Investors can access a live audio webcast through AbbVie's Investor Relations website, with an archived version available later that day. AbbVie focuses on innovative medicines across various therapeutic areas, including immunology and oncology.
AbbVie announced the European Commission's approval of SKYRIZI (risankizumab) as the first IL-23 inhibitor for treating adults with moderately to severely active Crohn's disease. This approval, significant for patients with inadequate responses to other therapies, is supported by the Phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Results indicated that patients on SKYRIZI showed better clinical remission and endoscopic response rates at both 12 and 52 weeks compared to placebo. The treatment is integral to AbbVie's growing IBD portfolio, aiming to alleviate symptoms and improve patient outcomes.
AbbVie (NYSE: ABBV) will present nearly 65 abstracts, including 15 oral presentations, at the upcoming American Society of Hematology (ASH) annual congress from December 10-13, 2022. The presentations will cover 8 types of blood cancers, highlighting investigational and approved therapies such as epcoritamab and navitoclax. Data aims to showcase advancements in treating chronic lymphocytic leukemia and multiple myeloma. The company emphasizes a commitment to improving patient outcomes in blood cancers, although many therapies are still under evaluation and not yet approved.
AbbVie (NYSE: ABBV) will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 8:30 a.m. Central time. Key executives, including Rob Michael and Scott Reents, will participate. A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later that day. AbbVie focuses on innovative medicines across therapeutic areas such as immunology and oncology.
AbbVie celebrated its fourth annual BOTOX® Cosmetic Day, achieving record-breaking participation and sales. The event marked the highest single treatment day in the brand's 20-year history, with over 285,000 site visitors within the first hour. Allē registrations hit a new peak, and BOGO gift cards sold out, exceeding 2021 sales by 20%. The brand experienced a 130% increase in searches for local providers. These metrics reflect heightened consumer interest and satisfaction with BOTOX® Cosmetic, which remains the only FDA-approved treatment for specific facial lines.
On November 9, 2022, AbbVie (NYSE: ABBV) announced its participation in the 4th Annual Wolfe Research Healthcare Conference scheduled for November 15, 2022, at 10:30 a.m. CT. Key executives, including Rob Michael and Jeffrey Stewart, will present virtually. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session accessible later that day. AbbVie focuses on innovative medicines in various therapeutic areas, such as immunology, oncology, and neuroscience.
AbbVie (NYSE: ABBV) will present 36 abstracts at the American College of Rheumatology's annual meeting (ACR Convergence 2022), highlighting advancements in treatments for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Key data includes long-term safety analyses for RINVOQ® (upadacitinib) and SKYRIZI® (risankizumab). Notable presentations cover major adverse cardiovascular events in clinical trials and the impact of second-line therapies on disease control. These findings underscore AbbVie's ongoing commitment to innovation in rheumatology.
AbbVie announced results from its NOVA phase 2 study evaluating AGN-151607 for preventing postoperative atrial fibrillation (POAF) in cardiac surgery patients. Although the primary endpoint was not met, the data indicated a significant 29% relative risk reduction for CABG patients treated with 125 units. Moreover, those aged 65 and older showed a 51% risk reduction. The study also reported lower 30-day rehospitalization rates (8.7% vs. 15.7%) and more patients being atrial fibrillation-free (62.9% vs. 45.1%). Adverse events were similar across treatment groups, highlighting AGN-151607's potential in specific populations.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), expands its Pink Ribbon Strong 365 campaign, dedicated to year-round support for breast cancer patients, survivors, and previvors. The initiative emphasizes education and empowerment, offering resources like the Natrelle Cares Package and the Natrelle Inspires Bra, which donates one bra for every purchase. The campaign also includes an award-winning documentary and partnerships with organizations like METAvivor. Allergan aims to raise awareness and provide comprehensive support beyond Breast Cancer Awareness Month.
Summary not available.